A Biocompatible Poly(amidoamine) (PAMAM) Dendrimer Octa-substituted with α-cyclodextrin Towards the Controlled Release of Doxorubicin Hydrochloride from Its Ferrocenyl Prodrug

Overview

Journal RSC Adv

Publisher Royal Society of Chemistry

Specialty Chemistry

Date 2022 May 6

PMID 35520312

Authors

Artur Kasprzak

Bartlomiej Dabrowski

Agnieszka Zuchowska

Affiliations

Soon will be listed here.

Abstract

Facile and efficient methods for the synthesis of the first poly(aminodamine) PAMAM G1.0 dendrimer octa-substituted with α-cyclodextrin and a novel ferrocenyl prodrug of doxorubicin hydrochloride are developed. This vector is non-toxic and can bind the designed ferrocenyl prodrug. It also shows a controlled drug release profile and high cytotoxicity against breast cancer cells (MCF-7), as elucidated by the biological studies performed with an innovative cell-on-a-chip microfluidic system.

Citing Articles

Using Poly(amidoamine) PAMAM-βCD Dendrimer for Controlled and Prolonged Delivery of Doxorubicin as Alternative System for Cancer Treatment.

Sorroza-Martinez K, Gonzalez-Sanchez I, Villamil-Ramos R, Cerbon M, Guerrero-Alvarez J, Coronel-Cruz C Pharmaceutics. 2025; 16(12.

PMID: 39771488 PMC: 11728618. DOI: 10.3390/pharmaceutics16121509.

References

Szillat F, Schmidt B, Hubert A, Barner-Kowollik C, Ritter H . Redox-switchable supramolecular graft polymer formation via ferrocene-cyclodextrin assembly. Macromol Rapid Commun. 2014; 35(14):1293-300. DOI: 10.1002/marc.201400122. View

Mao H, Qian F, Li S, Shen J, Ye C, Hua L . Delivery of Doxorubicin from Hyaluronic Acid-Modified Glutathione-Responsive Ferrocene Micelles for Combination Cancer Therapy. Mol Pharm. 2019; 16(3):987-994. DOI: 10.1021/acs.molpharmaceut.8b00862. View

Ferrazza R, Rossi B, Guella G . DOSY-NMR and raman investigations on the self-aggregation and cyclodextrin complexation of vanillin. J Phys Chem B. 2014; 118(25):7147-55. DOI: 10.1021/jp504406j. View

Arima H, Motoyama K . Recent Findings Concerning PAMAM Dendrimer Conjugates with Cyclodextrins as Carriers of DNA and RNA. Sensors (Basel). 2012; 9(8):6346-61. PMC: 3312448. DOI: 10.3390/s90806346. View

Abdelwahab A, Ohyama A, Higashi T, Motoyama K, Khaled K, Sarhan H . Preparation and evaluation of polyamidoamine dendrimer conjugate with glucuronylglucosyl-β-cyclodextrin (G3) as a novel carrier for siRNA. J Drug Target. 2014; 22(10):927-34. DOI: 10.3109/1061186X.2014.950663. View

Kojima C, Toi Y, Harada A, Kono K . Aqueous solubilization of fullerenes using poly(amidoamine) dendrimers bearing cyclodextrin and poly(ethylene glycol). Bioconjug Chem. 2008; 19(11):2280-4. DOI: 10.1021/bc8001503. View

Lao J, Madani J, Puertolas T, Alvarez M, Hernandez A, Pazo-Cid R . Liposomal Doxorubicin in the treatment of breast cancer patients: a review. J Drug Deliv. 2013; 2013:456409. PMC: 3619536. DOI: 10.1155/2013/456409. View

Altreuter D, Dordick J, Clark D . Nonaqueous biocatalytic synthesis of new cytotoxic doxorubicin derivatives: exploiting unexpected differences in the regioselectivity of salt-activated and solubilized subtilisin. J Am Chem Soc. 2002; 124(9):1871-6. DOI: 10.1021/ja015977y. View

Arima H, Kihara F, Hirayama F, Uekama K . Enhancement of gene expression by polyamidoamine dendrimer conjugates with alpha-, beta-, and gamma-cyclodextrins. Bioconjug Chem. 2001; 12(4):476-84. DOI: 10.1021/bc000111n. View

10.

Hagen H, Marzenell P, Jentzsch E, Wenz F, Veldwijk M, Mokhir A . Aminoferrocene-based prodrugs activated by reactive oxygen species. J Med Chem. 2011; 55(2):924-34. DOI: 10.1021/jm2014937. View

11.

Gidwani B, Vyas A . A Comprehensive Review on Cyclodextrin-Based Carriers for Delivery of Chemotherapeutic Cytotoxic Anticancer Drugs. Biomed Res Int. 2015; 2015:198268. PMC: 4637021. DOI: 10.1155/2015/198268. View

12.

Kato Y, Ozawa S, Miyamoto C, Maehata Y, Suzuki A, Maeda T . Acidic extracellular microenvironment and cancer. Cancer Cell Int. 2013; 13(1):89. PMC: 3849184. DOI: 10.1186/1475-2867-13-89. View

13.

Najjar A, Karaman R . The prodrug approach in the era of drug design. Expert Opin Drug Deliv. 2018; 16(1):1-5. DOI: 10.1080/17425247.2019.1553954. View

14.

Wang Y, Wang H, Chen Y, Liu X, Jin Q, Ji J . pH and hydrogen peroxide dual responsive supramolecular prodrug system for controlled release of bioactive molecules. Colloids Surf B Biointerfaces. 2014; 121:189-95. DOI: 10.1016/j.colsurfb.2014.06.024. View

15.

Yan Q, Yuan J, Cai Z, Xin Y, Kang Y, Yin Y . Voltage-responsive vesicles based on orthogonal assembly of two homopolymers. J Am Chem Soc. 2010; 132(27):9268-70. DOI: 10.1021/ja1027502. View

16.

Kwapiszewska K, Michalczuk A, Rybka M, Kwapiszewski R, Brzozka Z . A microfluidic-based platform for tumour spheroid culture, monitoring and drug screening. Lab Chip. 2014; 14(12):2096-104. DOI: 10.1039/c4lc00291a. View

17.

Shafei A, El-Bakly W, Sobhy A, Wagdy O, Reda A, Aboelenin O . A review on the efficacy and toxicity of different doxorubicin nanoparticles for targeted therapy in metastatic breast cancer. Biomed Pharmacother. 2017; 95:1209-1218. DOI: 10.1016/j.biopha.2017.09.059. View

18.

Cheetham A, Chakroun R, Ma W, Cui H . Self-assembling prodrugs. Chem Soc Rev. 2017; 46(21):6638-6663. PMC: 5844511. DOI: 10.1039/c7cs00521k. View

19.

Tacar O, Sriamornsak P, Dass C . Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol. 2013; 65(2):157-70. DOI: 10.1111/j.2042-7158.2012.01567.x. View

20.

Crini G . Review: a history of cyclodextrins. Chem Rev. 2014; 114(21):10940-75. DOI: 10.1021/cr500081p. View